Genscript Biotech Corporation Share Price
Equities
1548
KYG3825B1059
Biotechnology & Medical Research
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.38 HKD | -5.89% |
|
+5.82% | +15.62% |
| 04-14 | Genscript Biotech Associate Logs $597 Million in Q1 Sales of Carvykti | MT |
| 04-02 | Jefferies Adjusts Yeahka's Price Target to HK$15.50 From HK$23, Keeps at Buy | MT |
| Capitalization | 4.27B 33.43B 3.62B 3.32B 3.13B 5.84B 407B 5.88B 39.36B 15.36B 194B 16.02B 15.69B 671B | P/E ratio 2026 * |
49.1x | P/E ratio 2027 * | 20.8x |
|---|---|---|---|---|---|
| Enterprise value | 4.23B 33.11B 3.59B 3.29B 3.1B 5.78B 403B 5.83B 38.98B 15.21B 192B 15.87B 15.53B 664B | EV / Sales 2026 * |
5.18x | EV / Sales 2027 * | 4.48x |
| Free-Float |
55.33% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Genscript Biotech Corporation
| 1 day | -4.45% | ||
| 1 week | +7.59% | ||
| Current month | +6.41% | ||
| 1 month | +15.69% | ||
| 3 months | +18.03% | ||
| 6 months | -14.92% | ||
| Current year | +17.55% |
| 1 week | 14.02 |  | 15.68 |
| 1 month | 12.55 | | 15.68 |
| Current year | 10.36 | | 15.68 |
| 1 year | 9.95 | | 19.4 |
| 3 years | 7.43 | | 24.95 |
| 5 years | 7.43 | | 43.4 |
| 10 years | 1.07 | | 43.4 |
| Manager | Title | Age | Since |
|---|---|---|---|
Weihui Shao
CEO | Chief Executive Officer | - | 31/12/2022 |
Ye Wang
PSD | President | 57 | 30/11/2017 |
Josie Zhou
DFI | Director of Finance/CFO | - | 30/04/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Ye Wang
BRD | Director/Board Member | 57 | 20/05/2015 |
Jian Ge Meng
CHM | Chairman | 57 | 21/11/2020 |
Li Zhu
BRD | Director/Board Member | 76 | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.25% | +7.59% | +38.00% | -23.32% | 4.25B | |
| -0.25% | +0.54% | -17.61% | -16.47% | 43.39B | |
| -0.44% | +4.58% | +33.95% | +27.04% | 34.7B | |
| +1.65% | -2.54% | +256.63% | +462.65% | 30.15B | |
| -2.89% | +7.84% | +16.48% | -8.60% | 29.83B | |
| -3.58% | -3.29% | +25.92% | +23.90% | 28.46B | |
| +0.00% | +4.35% | - | - | 14.82B | |
| -6.66% | -0.11% | +183.75% | +4,189.75% | 14.48B | |
| -0.44% | -0.09% | +133.66% | +111.80% | 12.51B | |
| -1.38% | +1.14% | +3.87% | -3.43% | 12.29B | |
| Average | -1.84% | +3.14% | +74.96% | +529.26% | 22.49B | |
| Weighted average by Cap. | -1.34% | +2.49% | +66.28% | +364.27% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 816M 6.39B 692M 634M 598M 1.11B 77.72B 1.12B 7.52B 2.93B 37.02B 3.06B 3B 128B | 931M 7.29B 790M 724M 682M 1.27B 88.71B 1.28B 8.58B 3.35B 42.25B 3.49B 3.42B 146B |
| Net income | 74.8M 586M 63.48M 58.13M 54.81M 102M 7.13B 103M 689M 269M 3.39B 281M 275M 11.75B | 219M 1.71B 186M 170M 160M 299M 20.84B 301M 2.02B 787M 9.93B 821M 804M 34.35B |
| Net Debt | -41.64M -326M -35.34M -32.36M -30.51M -56.91M -3.97B -57.37M -384M -150M -1.89B -156M -153M -6.54B | -102M -802M -86.92M -79.6M -75.05M -140M -9.76B -141M -944M -368M -4.65B -384M -376M -16.08B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/05/26 | 14.38 $ | -5.89% | 6,840,011 |
| 11/05/26 | 15.28 $ | +0.46% | 8,956,253 |
| 08/05/26 | 15.21 $ | -1.74% | 9,427,332 |
| 07/05/26 | 15.48 $ | +7.43% | 31,644,430 |
| 06/05/26 | 14.41 $ | +6.19% | 16,378,280 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 1548 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition